[go: up one dir, main page]

AR088383A1 - Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles - Google Patents

Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles

Info

Publication number
AR088383A1
AR088383A1 ARP120103889A ARP120103889A AR088383A1 AR 088383 A1 AR088383 A1 AR 088383A1 AR P120103889 A ARP120103889 A AR P120103889A AR P120103889 A ARP120103889 A AR P120103889A AR 088383 A1 AR088383 A1 AR 088383A1
Authority
AR
Argentina
Prior art keywords
polyols
sugars
formulations
combinations
etanercept
Prior art date
Application number
ARP120103889A
Other languages
English (en)
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AR088383A1 publication Critical patent/AR088383A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica acuosa y estable que comprende etanercept en combinación con estabilizadores para reducir la inestabilidad, el plegamiento erróneo de la agregación y/o la fragmentación del etanercept durante el almacenamiento de la formulación; donde dicho estabilizador comprende una combinación de un azúcar y un poliol.
ARP120103889A 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles AR088383A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09

Publications (1)

Publication Number Publication Date
AR088383A1 true AR088383A1 (es) 2014-05-28

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP120103889A AR088383A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio
ARP120103885A AR088379A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos

Family Applications After (5)

Application Number Title Priority Date Filing Date
ARP120103887A AR088381A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con meglumina
ARP120103886A AR088380A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con cloruro de sodio
ARP120103885A AR088379A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con iones metalicos
ARP120103888A AR088382A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con xilitol
ARP120103884A AR088460A1 (es) 2011-10-18 2012-10-18 Formulaciones de etanercept estabilizadas con aminoacidos

Country Status (28)

Country Link
US (21) US10293049B2 (es)
EP (6) EP2768531A4 (es)
JP (6) JP6113176B2 (es)
KR (7) KR20140091707A (es)
CN (6) CN103998061A (es)
AR (6) AR088383A1 (es)
AU (6) AU2012326084B2 (es)
BR (6) BR112014009073A2 (es)
CA (6) CA2851639C (es)
CY (1) CY1121843T1 (es)
DK (1) DK2768525T3 (es)
EA (6) EA026410B1 (es)
ES (1) ES2734070T3 (es)
HK (3) HK1200721A1 (es)
HR (1) HRP20191215T1 (es)
HU (1) HUE045624T2 (es)
IL (6) IL231827A0 (es)
IN (3) IN2014CN02591A (es)
LT (1) LT2768525T (es)
MX (7) MX2014004732A (es)
PL (1) PL2768525T3 (es)
PT (1) PT2768525T (es)
RS (1) RS59179B1 (es)
SG (6) SG11201401567YA (es)
SI (1) SI2768525T1 (es)
SM (1) SMT201900422T1 (es)
TW (6) TW201325606A (es)
WO (6) WO2013059407A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
EA026410B1 (ru) * 2011-10-18 2017-04-28 Кохерус Байосайенсис, Инк. Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
BR112015000203A2 (pt) * 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
WO2014043103A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US20160106844A1 (en) * 2013-05-02 2016-04-21 Mabxience, S.A. Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
CN119971024A (zh) * 2013-10-24 2025-05-13 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CA2930227C (en) * 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3207936B1 (en) 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
ES2833506T3 (es) * 2014-12-22 2021-06-15 Ares Trading Sa Composición farmacéutica líquida
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
MX394035B (es) * 2014-12-31 2025-03-21 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
CA3040899A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
BR112020010761A2 (pt) * 2017-11-30 2020-11-24 Bio-Thera Solutions, Ltd. formulação líquida de anticorpo humanizado para o tratamento de doenças relacionadas à il-6
JP7692699B2 (ja) * 2017-12-22 2025-06-16 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20220122993A (ko) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 바이오폴리머 제형을 위한 부형제 화합물
CN116867481A (zh) 2021-02-17 2023-10-10 艾瑞克有限公司 包含Fc结构域的工程化蛋白质构建体的水性组合物
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
CA2123593C (en) 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
PL213501B1 (pl) * 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
RS54573B1 (sr) 2003-10-14 2016-06-30 F. Hoffmann-La Roche Ltd Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
ES2456015T3 (es) 2004-03-05 2014-04-21 Dsm Ip Assets B.V. Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
ES2776657T3 (es) * 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
CA2634131C (en) * 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
US20100016677A1 (en) 2006-03-21 2010-01-21 Eugen Oetringer Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
PE20080857A1 (es) 2006-10-20 2008-08-19 Amgen Inc Formulaciones a base de polipeptidos estables
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
JP5586235B2 (ja) 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
HUE041555T2 (hu) 2007-06-14 2019-05-28 Biogen Ma Inc Natalizumab antitest készítmények formulációk
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
CN102239177A (zh) 2008-02-29 2011-11-09 比奥根艾迪克Ma公司 纯化的免疫球蛋白融合蛋白及其纯化方法
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
CA2770690C (en) 2009-08-11 2021-03-09 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
US20130209465A1 (en) 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
JP5996631B2 (ja) * 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CA2840626A1 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
CA2840951A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Methods for purifying fc-fusion protein
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
EA026410B1 (ru) * 2011-10-18 2017-04-28 Кохерус Байосайенсис, Инк. Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
WO2014043103A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield

Also Published As

Publication number Publication date
EA201490801A1 (ru) 2014-09-30
WO2013059412A1 (en) 2013-04-25
HUE045624T2 (hu) 2020-01-28
JP6113176B2 (ja) 2017-04-12
BR112014009022A2 (pt) 2017-05-02
US9801942B2 (en) 2017-10-31
IN2014CN02592A (es) 2015-09-04
EA201490804A1 (ru) 2014-09-30
EP2768535A4 (en) 2015-03-11
AU2012326080A1 (en) 2014-04-24
MX2014004732A (es) 2015-05-15
CN103998060B (zh) 2016-12-21
KR20140091705A (ko) 2014-07-22
US11129876B2 (en) 2021-09-28
AR088379A1 (es) 2014-05-28
WO2013059407A1 (en) 2013-04-25
IL231828A0 (en) 2014-05-28
PT2768525T (pt) 2019-07-17
AU2012326168A1 (en) 2014-04-24
AU2012326168B2 (en) 2016-12-15
TW201325607A (zh) 2013-07-01
EP2768533A4 (en) 2015-03-11
HRP20191215T1 (hr) 2019-10-04
CN104010657A (zh) 2014-08-27
US20190290766A1 (en) 2019-09-26
US10213508B2 (en) 2019-02-26
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
US20190314498A1 (en) 2019-10-17
JP2014530256A (ja) 2014-11-17
US20130108633A1 (en) 2013-05-02
KR20140097184A (ko) 2014-08-06
TWI595883B (zh) 2017-08-21
EP2768532A1 (en) 2014-08-27
EP2768525A4 (en) 2015-07-15
RS59179B1 (sr) 2019-10-31
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (en) 2013-04-25
CA2851639C (en) 2020-12-29
US20180125982A1 (en) 2018-05-10
BR112014009131A2 (pt) 2017-06-13
US10772963B2 (en) 2020-09-15
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (es) 2015-06-26
MX2014004725A (es) 2015-02-05
AU2012326084B2 (en) 2016-12-15
MX2014004728A (es) 2015-05-15
JP2014530254A (ja) 2014-11-17
JP2014530862A (ja) 2014-11-20
AU2012326170A1 (en) 2014-04-24
TWI619504B (zh) 2018-04-01
BR112014009073A2 (pt) 2017-05-09
JP6110393B2 (ja) 2017-04-05
CA2851628A1 (en) 2013-04-25
MX2019009176A (es) 2019-10-07
US20130101640A1 (en) 2013-04-25
EP2768525A1 (en) 2014-08-27
ES2734070T3 (es) 2019-12-04
JP2014530863A (ja) 2014-11-20
US20190216930A1 (en) 2019-07-18
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
EA201490803A1 (ru) 2014-09-30
TW201325610A (zh) 2013-07-01
US10980884B2 (en) 2021-04-20
US20160199489A1 (en) 2016-07-14
HK1200851A1 (en) 2015-08-14
IL231825A0 (en) 2014-05-28
US10376588B2 (en) 2019-08-13
CA2851646A1 (en) 2013-04-25
AU2012326170B2 (en) 2016-12-22
BR112014009146A8 (pt) 2017-06-20
WO2013059408A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
US20130108632A1 (en) 2013-05-02
BR112014009131A8 (pt) 2017-06-20
US20180193463A1 (en) 2018-07-12
KR20200008021A (ko) 2020-01-22
KR20140091707A (ko) 2014-07-22
US20190290767A1 (en) 2019-09-26
IL231824A0 (en) 2014-05-28
US11135267B2 (en) 2021-10-05
MX2014004733A (es) 2015-05-15
TW201325608A (zh) 2013-07-01
EP2768531A4 (en) 2015-03-11
US20130101584A1 (en) 2013-04-25
EP2768535A1 (en) 2014-08-27
AR088460A1 (es) 2014-06-11
EA025267B1 (ru) 2016-12-30
US10987405B2 (en) 2021-04-27
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
HK1200721A1 (en) 2015-08-14
US20200405865A1 (en) 2020-12-31
CN104010658A (zh) 2014-08-27
AU2012326082A1 (en) 2014-04-24
KR20140091706A (ko) 2014-07-22
JP2014530255A (ja) 2014-11-17
TW201325609A (zh) 2013-07-01
IN2014CN02527A (es) 2015-06-26
KR102068462B1 (ko) 2020-01-22
CA2851651A1 (en) 2013-04-25
AU2012326171B2 (en) 2017-03-09
TW201325606A (zh) 2013-07-01
SMT201900422T1 (it) 2019-09-09
TWI644681B (zh) 2018-12-21
CA2851635A1 (en) 2013-04-25
BR112014009087A2 (pt) 2017-04-18
AR088380A1 (es) 2014-05-28
US20190184017A1 (en) 2019-06-20
EP2768533A1 (en) 2014-08-27
AR088381A1 (es) 2014-05-28
JP2014530864A (ja) 2014-11-20
CY1121843T1 (el) 2020-07-31
MX2014004726A (es) 2015-05-15
AU2012326080B2 (en) 2017-02-16
JP6199298B2 (ja) 2017-09-20
TW201325611A (zh) 2013-07-01
IL231827A0 (en) 2014-05-28
EA025663B1 (ru) 2017-01-30
US9770510B2 (en) 2017-09-26
US20160317667A1 (en) 2016-11-03
SG11201401517VA (en) 2014-09-26
DK2768525T3 (da) 2019-07-22
BR112014009146A2 (pt) 2017-06-13
JP6220789B2 (ja) 2017-10-25
SG11201401562RA (en) 2014-09-26
CN104010654B (zh) 2017-10-27
EA026410B1 (ru) 2017-04-28
SG11201401576WA (en) 2014-10-30
EP2768532A4 (en) 2015-03-11
US20190290768A1 (en) 2019-09-26
US20190290765A1 (en) 2019-09-26
US9302002B2 (en) 2016-04-05
IL231829A0 (en) 2014-05-28
EP2768854A1 (en) 2014-08-27
CN104011073B (zh) 2017-08-25
IL231826A0 (en) 2014-05-28
EA201490817A1 (ru) 2014-09-30
EA201490802A1 (ru) 2014-08-29
HK1200720A1 (en) 2015-08-14
US10888619B2 (en) 2021-01-12
KR20140083037A (ko) 2014-07-03
US9943601B2 (en) 2018-04-17
AU2012326084A1 (en) 2014-04-17
SG11201401563SA (en) 2014-09-26
EP2768531A1 (en) 2014-08-27
EA027325B1 (ru) 2017-07-31
HK1200718A1 (en) 2015-08-14
CN103998060A (zh) 2014-08-20
SI2768525T1 (sl) 2019-10-30
EP2768854A4 (en) 2015-03-11
CN104010654A (zh) 2014-08-27
SG11201401519RA (en) 2014-07-30
MX367054B (es) 2019-08-02
KR20140079491A (ko) 2014-06-26
SG11201401567YA (en) 2014-07-30
HK1200722A1 (en) 2015-08-14
PL2768525T3 (pl) 2019-10-31
LT2768525T (lt) 2019-09-25
US20190314500A1 (en) 2019-10-17
CN103998061A (zh) 2014-08-20
CA2851642A1 (en) 2013-04-25
US20190314499A1 (en) 2019-10-17
EA201490815A1 (ru) 2014-09-30
MX2014004734A (es) 2015-05-15
KR102163150B1 (ko) 2020-10-08
EP2768525B1 (en) 2019-06-19
AU2012326171A1 (en) 2014-04-24
WO2013059406A1 (en) 2013-04-25
CA2851639A1 (en) 2013-04-25
US20190298837A1 (en) 2019-10-03
AR088382A1 (es) 2014-05-28
JP6104922B2 (ja) 2017-03-29
US10980885B2 (en) 2021-04-20
BR112014009031A2 (pt) 2017-05-09
JP6220788B2 (ja) 2017-10-25

Similar Documents

Publication Publication Date Title
AR088383A1 (es) Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
PE20151425A1 (es) Formulaciones farmaceuticas muy concentradas que comprenden un anticuerpo anti-cd20
CO7111300A2 (es) Formulación de anticuerpos
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CO7151487A2 (es) Formulación de anticuerpos
BR112014004460A2 (pt) material polimérico para um recipiente isolado
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
PH12015501623A1 (en) Glyco-modified atrial natriuretic peptide
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR086956A1 (es) Formulaciones liofilizadas de fgf-18
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX385093B (es) Formulaciones de espuma y aparatos para su suministro.
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
NI201600006A (es) Pirazolo-piridinaminas sustituidas
MX2015008528A (es) Formulaciones para conservacion de organos y tejidos con estabilidad y vida util aumentadas.
BR112017026666A2 (pt) armazenagem de longo prazo e conservação de plaquetas
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
CO6470844A2 (es) Solución bebible farmacéutica de telmisartan
NZ603783A (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant

Legal Events

Date Code Title Description
FB Suspension of granting procedure